+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Nucleic Acid Therapeutics CDMO Market - Global Forecast 2026-2032- Product Image
Nucleic Acid Therapeutics CDMO Market - Global Forecast 2026-2032- Product Image
New

Nucleic Acid Therapeutics CDMO Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 188 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6013697
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The nucleic acid therapeutics CDMO market is evolving rapidly as scientific innovations meet complex commercialization and regulatory demands. Senior executives require precise insights to navigate shifting operational priorities, technology adoption, and partnership models. This report provides strategic intelligence for leaders aiming to capture value and minimize risk in a dynamic environment.

Market Snapshot: Nucleic Acid Therapeutics CDMO Market Growth and Trends

The nucleic acid therapeutics CDMO market grew from USD 12.00 billion in 2025 to USD 13.36 billion in 2026. It is expected to continue growing at a CAGR of 11.76%, reaching USD 26.14 billion by 2032. Robust expansion is driven by scientific breakthroughs, new therapy modalities, and increasing requirements for end-to-end development and manufacturing.

Scope & Segmentation

This report comprehensively covers the multifaceted nucleic acid therapeutics CDMO market, analyzing critical segments, regions, and technologies that drive competitive decision-making:

  • Therapeutics Type: DNA therapeutics and RNA therapeutics, each with distinct process engineering, analytical, and delivery requirements.
  • Service Type: Analytical testing and quality control, manufacturing, packaging and distribution, and process development and optimization as core areas of demand.
  • Therapeutic Applications: Oncology, infectious diseases, neurological disorders, genetic disorders, and rare disorders, each shaping service needs and clinical complexity.
  • End Users: Academic and research institutes, biotechnology firms, and pharmaceutical companies—each with unique partnership and resource expectations.
  • Regional Insights: Americas, Europe, Middle East & Africa, Asia-Pacific; factors influencing site selection, regulatory strategy, and supply chain design by geography.
  • Technology Platforms: Advanced vector engineering, delivery platforms, analytical methods, manufacturing automation, digital controls, and predictive analytics for process efficiency and compliance.

Key Takeaways for Senior Decision-Makers

  • Nucleic acid therapeutics contract manufacturing is shifting from narrowly defined services toward integrated, capability-driven offerings, aligning technical depth and cross-functional processes to deliver sponsor value.
  • Heightened regulatory expectations, especially for control strategies and analytical rigor, are compelling firms to enhance quality systems and invest in advanced characterization and process controls.
  • Strategic partnerships now emphasize collaboration beyond manufacturing—including co-development, lifecycle management, and technology transfer—enabling accelerated program progression and commercial readiness.
  • Supply chain resilience is prioritized, with diversification of procurement channels, regional manufacturing, and adoption of digital planning tools to ensure reliable supply and mitigate material shortages.
  • Competitive differentiation increasingly depends on scientific leadership, modular manufacturing, and commercial agility, enabling firms to secure, retain, and scale sponsor partnerships over the program lifecycle.
  • Investment in talent, cross-functional teams, and proven regulatory engagement is essential for efficient program transfer, reduced risk, and meeting global compliance standards.

Tariff Impact: Navigating 2025 Trade Policy Dynamics

Recent tariff policy changes have heightened focus on supply chain strategy and regional manufacturing for the nucleic acid therapeutics CDMO sector. Companies are adapting by localizing critical raw materials, expanding dual-source arrangements, and considering nearshoring for cost- and policy-sensitive production stages. This approach helps absorb cost volatility and supports margin protection as further trade adjustments arise. Organizations with geographically flexible manufacturing networks and robust site-selection strategies are better positioned to navigate regulatory trade-offs and ongoing policy shifts.

Methodology & Data Sources

This report applies a mixed-methods approach—integrating primary interviews with program leaders, technical dossier reviews, and secondary analysis of regulatory guidance and partnership trends. All insights are validated through practitioner input and technical review, ensuring recommendations are practical, current, and actionable.

Why This Report Matters

  • Enables senior leaders to benchmark current capabilities against evolving market and regulatory requirements, guiding targeted investment and operational focus.
  • Equips stakeholders to de-risk manufacturing and partnership decisions through segment-driven intelligence on technology trends and regional variability.
  • Offers actionable frameworks for building supply resilience, deepening strategic relationships, and managing regulatory engagement for accelerated delivery of therapeutics.

Conclusion

The nucleic acid therapeutics CDMO landscape rewards strategic alignment of technical, commercial, and regulatory priorities. Those who invest in differentiated capabilities, integrated partnerships, and robust supply chains will be positioned for sustained growth and successful therapeutic delivery.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Nucleic Acid Therapeutics CDMO Market, by Therapeutics Type
8.1. DNA Therapeutics
8.2. RNA Therapeutics
9. Nucleic Acid Therapeutics CDMO Market, by Service Type
9.1. Analytical Testing & Quality Control
9.2. Manufacturing
9.3. Packaging & Distribution
9.4. Process Development & Optimization
10. Nucleic Acid Therapeutics CDMO Market, by Therapeutic Applications
10.1. Genetic Disorders
10.2. Infectious Diseases
10.3. Neurological Disorders
10.4. Oncology
10.5. Rare Disorders
11. Nucleic Acid Therapeutics CDMO Market, by End User
11.1. Academic & Research Institutes
11.2. Biotechnology Firms
11.3. Pharmaceutical Companies
12. Nucleic Acid Therapeutics CDMO Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Nucleic Acid Therapeutics CDMO Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Nucleic Acid Therapeutics CDMO Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Nucleic Acid Therapeutics CDMO Market
16. China Nucleic Acid Therapeutics CDMO Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. AGC Biologics Inc.
17.6. Agilent Technologies, Inc.
17.7. Ajinomoto Bio-Pharma Services
17.8. Almac Group Ltd.
17.9. Biomay AG
17.10. BioSpring GmbH
17.11. Catalent, Inc.
17.12. Charles River Laboratories International, Inc.
17.13. CordenPharma International GmbH
17.14. Creative Biogene
17.15. Danaher Corporation
17.16. Eurofins Scientific SE
17.17. Evonik Industries AG
17.18. GenScript Biotech Corporation
17.19. Lonza Group Ltd.
17.20. Polypeptide Group AG
17.21. Recipharm AB
17.22. Rentschler Biopharma SE
17.23. Samsung Biologics
17.24. The Scripps Research Institute
17.25. Touchlight Group
17.26. Univercells Group
17.27. WuXi AppTec Co., Ltd.
List of Figures
FIGURE 1. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 50. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
TABLE 51. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 52. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 53. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 54. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
TABLE 56. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 57. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 58. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 59. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
TABLE 61. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 62. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 63. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 64. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 65. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
TABLE 66. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 67. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 68. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 69. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
TABLE 71. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 72. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 73. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 74. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
TABLE 76. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 77. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 78. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 79. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
TABLE 81. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 82. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 83. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
TABLE 92. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 93. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 94. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 95. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
TABLE 97. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 98. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 99. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 100. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
TABLE 102. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 103. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 104. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 105. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
TABLE 107. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 108. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 109. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
TABLE 112. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 113. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 114. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 115. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
TABLE 117. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 118. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 119. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 122. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
TABLE 123. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 124. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 125. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 126. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 127. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2032 (USD MILLION)
TABLE 128. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 129. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2032 (USD MILLION)
TABLE 130. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Nucleic Acid Therapeutics CDMO market report include:
  • AGC Biologics Inc.
  • Agilent Technologies, Inc.
  • Ajinomoto Bio-Pharma Services
  • Almac Group Ltd.
  • Biomay AG
  • BioSpring GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • CordenPharma International GmbH
  • Creative Biogene
  • Danaher Corporation
  • Eurofins Scientific SE
  • Evonik Industries AG
  • GenScript Biotech Corporation
  • Lonza Group Ltd.
  • Polypeptide Group AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • The Scripps Research Institute
  • Touchlight Group
  • Univercells Group
  • WuXi AppTec Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages188
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 13.36 Billion
Forecasted Market Value ( USD ) by 2032 $ 26.14 Billion
Compound Annual Growth Rate11.7%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Nucleic Acid Therapeutics CDMO - Global Strategic Business Report - Product Image

Nucleic Acid Therapeutics CDMO - Global Strategic Business Report

  • Report
  • 200 Pages
  • Global
From
Nucleic Acid Therapeutics CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Nucleic Acid Therapeutics CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Peptide and Oligonucleotide CDMO - Global Strategic Business Report - Product Image

Peptide and Oligonucleotide CDMO - Global Strategic Business Report

  • Report
  • 370 Pages
  • Global
From
mRNA Therapeutics CDMO Market Report 2025 - Product Image

mRNA Therapeutics CDMO Market Report 2025

  • Report
  • 250 Pages
  • Global
From
mRNA CDMO Service Market - Global Forecast 2025-2030 - Product Image

mRNA CDMO Service Market - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From

About the Market

The Nucleic Acid Therapeutics CDMO market is a subset of the Pharmaceutical Manufacturing industry. It focuses on the production of nucleic acid-based drugs, such as DNA and RNA-based therapeutics, for use in the treatment of various diseases. These drugs are produced using a variety of techniques, including gene therapy, gene editing, and gene silencing. The market is driven by the increasing demand for personalized medicines, as well as the need for more efficient and cost-effective production methods. The Nucleic Acid Therapeutics CDMO market is highly competitive, with a number of companies offering services in the field. These include companies such as Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Moderna Therapeutics. Other companies in the market include Cellectis, CRISPR Therapeutics, and Intellia Therapeutics. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.